Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

Q&A med Genmabs CEO, 4 March Kl. 16 Læs mere her
      
side 1 / 249
Opret nyt indlæg

Her er min favoritindikator over dem alle!
23/2 18:42 Hans-Henrik Nielsen Svar: 0

Novo
23/2 18:27 exitnu Svar: 0

FLS
22/2 13:12 Klarussen Svar: 0

Optur i Genmab - Men er beartrenden brudt i..
21/2 22:44 Hans-Henrik Nielsen Svar: 3

Giver Alk-abello mig søvnløse nætter?
21/2 11:21 Hans-Henrik Nielsen Svar: 0

NKT tage profit eller højere op, PE -25 !
20/2 11:29 JonM Svar: 3

Daratumumab Prescription and Sales
20/2 11:12 JørgenVarnæs Svar: 0

Så købte jeg Fingerprint til porteføljen
20/2 11:01 Hans-Henrik Nielsen Svar: 8

Er Bure Equity ved at være overkøbt?
19/2 10:17 Hans-Henrik Nielsen Svar: 0

Spændende TA-kandidater til den kommende uge
17/2 16:23 Hans-Henrik Nielsen Svar: 0

Markedet har ophævet tyngdeloven
15/2 17:56 Hans-Henrik Nielsen Svar: 1

Forventninger til kursstigning?
13/2 16:23 Steen Langkjær Svar: 0

TA giver mig køb på Alk-abello
13/2 10:44 Hans-Henrik Nielsen Svar: 0

Genmab Announces U.S. FDA Approval
12/2 07:21 Helge Larsen/PI-redaktør Svar: 0

Mine TA-overvejelser om Rockwool - salg ell..
11/2 10:59 Hans-Henrik Nielsen Svar: 0

Aktivt eller passivt forvaltet? Er det virk..
9/2 21:16 Hans-Henrik Nielsen Svar: 0

Moving average
9/2 19:31 donprebsi Svar: 1

Investorbattle - Hans-Henrik versus Helge
9/2 11:44 Helge Larsen/PI-redaktør Svar: 1

The groundbreaking Tisotumab Vedotin data
9/2 09:33 Helge Larsen/PI-redaktør Svar: 2

Short i Dow Jones igen
8/2 17:05 Hans-Henrik Nielsen Svar: 1

Hvad siger TA om Vestas, Matas og DSV efter..
8/2 10:04 Hans-Henrik Nielsen Svar: 0

Hvad siger TA om Teva op mod regnskabet
7/2 09:51 Hans-Henrik Nielsen Svar: 0

GENMAB: Præsentation med events i 2019
6/2 20:47 Helge Larsen/PI-redaktør Svar: 0

Alligator Bioscience -Tumor-directet immuno..
6/2 20:20 Helge Larsen/PI-redaktør Svar: 2

Anmeldelse: "Den tålmodige Investor af Helg..
6/2 20:11 Helge Larsen/PI-redaktør Svar: 0

TA siger køb i Bure Equity
6/2 11:01 Hans-Henrik Nielsen Svar: 2

Er Selinexor en konkurrent til Darzalex?
5/2 20:33 Leoalf85 Svar: 1

Min model er ikke perfekt - se her hvor den..
4/2 22:28 Hans-Henrik Nielsen Svar: 0

FED holder renten i ro - skal vi være bekym..
31/1 09:59 Hans-Henrik Nielsen Svar: 0

Så kom der gang i Dow - Men hvor længe?
30/1 22:03 Hans-Henrik Nielsen Svar: 3

TA dikterer udskiftning i porteføljen
30/1 08:37 Hans-Henrik Nielsen Svar: 3

En opdatering på min TA-portefølje for janu..
26/1 10:21 Hans-Henrik Nielsen Svar: 0

Bekymrende TA-signal i Danske Bank
25/1 10:08 Hans-Henrik Nielsen Svar: 0

Stærkt regnskab fra Scatec Solar
25/1 08:30 Helge Larsen/PI-redaktør Svar: 2

Indre værdi af en aktie
24/1 14:04 Ole Juel Svar: 2

Darzalex 2018 oversigt
24/1 13:05 peter12 Svar: 0

Fingerprint og Veloxis - Hvornår tager man ..
24/1 09:03 Hans-Henrik Nielsen Svar: 0

Fingerprint - Er opturen brudt?
23/1 22:01 Hans-Henrik Nielsen Svar: 0

Genmab
23/1 20:15 fillipa Svar: 7

Analysevideo fra Pareto om laksesektoren 2019
23/1 08:31 Helge Larsen/PI-redaktør Svar: 1

Genmab Dazalex/RTOR
22/1 18:52 jkj Svar: 0

Lidt optur i markedet skaber mulige købskan..
22/1 09:29 Hans-Henrik Nielsen Svar: 3

Dette er verdens 30 største fiske-opdrætsvi..
18/1 10:26 Helge Larsen/PI-redaktør Svar: 0

Hvad siger TA om Gomspace, Teva og Bavarian
18/1 09:08 Hans-Henrik Nielsen Svar: 0

Så rykker Fingerprint!
15/1 15:48 Hans-Henrik Nielsen Svar: 2

Dårligt nyt fra Kina - Men hvad med aktiern..
14/1 09:43 Hans-Henrik Nielsen Svar: 0

Virker TA eller er det rent fup?
12/1 17:25 Hans-Henrik Nielsen Svar: 7

Ny analyse fra ØU på Onkology Venture
8/1 20:22 Helge Larsen/PI-redaktør Svar: 0

Modregning gevinst/tab
8/1 19:25 gilroy Svar: 3


The groundbreaking Tisotumab Vedotin data

  



David Mygind Founder SLL dealer network på Linkedin d. 8 februar 2019:

"The groundbreaking Tisotumab Vedotin data from the Innova201 study is another example of world class antibody capabilities. It underlines once more how Genmab turns science into medicine and seems poised to dominate the immuno oncology scene of the future.
It is important to remember what the CEO said about Tisotumab Vedotin when the drug received its first media attention roughly 5 years ago.

http://bit.ly/genmab-could-be-hatching-golden-egg

The article in Borsen explained how Tisotumab Vedotin could be "THE BIG ONE". The safety profile was highlighted as something that could be problematic given that the molecule is 100 times more toxic (efficacious) than the most potent forms of chemotherapy.
The title describes Tisotumab Vedotin as a golden egg to be hatched. The data published yesterday in the Lancet of Oncology proves that something very valuable is indeed being hatched at Genmab. The data clearly shows manageable side effects while also revealing unparalleled efficacy in the late stage treatment of cervical cancer. This makes the drug destined for market launch in 2020 and it paves the way for quick penetration into the earlier lines of treatment.


The fact that mainstream media reported on the trial results today is a sign that awareness is bound to skyrocket soon. It is heartwarming to know that Tisotumab Vedotin will soon become available for cancer patients who exerted all other options. However, it is also exciting to consider how much value this will create for Genmab who are now again in the early days of another "oncology homerun" that will impact the prevailing treatment paradigm in several types of solid cancer.
I predict that Tisotumab Vedotin becomes a blockbuster drug that edges towards 2 billion in sales already within 5 years from now. The analysts have completely missed the boat and they will need to catch up rather sooner than later. The NPV implications will be staggering as we learn more over the next 1-2 years. Congratulations to Genmab, to the patients and to the shareholders.

BBC today (listen from 15 minutes and ahead):
https://www.bbc.co.uk/sounds/play/w172w1fzmnv6fx7
Daily Mail (tabloid press - highly unusual mainstream coverage):
https://www.dailymail.co.uk/health/article-6678373/Tr.. (edited) "



Kilde: https://www.linkedin.com/feed/update/urn:li:activity:..





The Lancet: Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial

Prof Johann S de Bono, MD
Prof Nicole Concin, MD
David S Hong, MD
Fiona C Thistlethwaite, MBBChir
Prof Jean-Pascal Machiels, MD
Hendrik-Tobias Arkenau, MD
et al.


Published:February 07, 2019DOI:https://doi.org/10.1016/S1470-2045(18)30859-3

Læs mere:

https://www.thelancet.com/journals/lanonc/article/PII..



Hidsig omtale af Tisotumab Vedotin:

https://www.sciencealert.com/this-new-trojan-horse-dr..

Helge Larsen/PI-redaktør 0 76689 11/2 2019 08:46 STEM OP SVAR



side 1 / 249
Opret nyt indlæg